PCR119 Treatment Persistence Among Treatment-Experienced People With HIV (PWH) Switching To Integrase Strand Transfer Inhibitor (INSTI)-Based HIV Antiretroviral Regimens

Autor: Chuo, CY, Christoph, MJ, Zachry, W, de Boer M, Chen, M, Trom, C

Publikováno v: In Value in Health June 2024 27(6) Supplement:S318-S318

CO192 A Retrospective Database Analysis of US Medicaid Treatment-Naive People With HIV (PWH) With or Without Mental Health Disorders (MHDs) Initiating Single-Tablet Regimens (STRs) Vs. Multi-Tablet Regimens (MTRs).

Autor: Chen, M.¹ (AUTHOR), Turkistani, F.² (AUTHOR), Weinberg, AR.¹ (AUTHOR), Christoph, MJ.¹ (AUTHOR), Gruber, J.¹ (AUTHOR), Trom, C.¹ (AUTHOR), Park, S.¹ (AUTHOR), Rajagopalan, K.³ (AUTHOR)

Publikováno v: Value in Health. 2024 Supplement, Vol. 27 Issue 6, pS53-S54. 2p.

Reply to "Letter to Dobesh et al. on lower mortality with andexanet alfa in factor Xa inhibitor-related major bleeding".

Autor: Dobesh PP; Department of Pharmacy Practice and Science, University of Nebraska Medical Center, College of Pharmacy, Omaha, Nebraska, USA., Fermann GJ; Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio, USA., Christoph MJ; AstraZeneca, Wilmington, Delaware, USA., Koch B; AstraZeneca, Wilmington, Delaware, USA., Lesén E; AstraZeneca, Gothenburg, Sweden., Chen H; AstraZeneca, Wilmington, Delaware, USA., Lovelace B; AstraZeneca, Wilmington, Delaware, USA., Dettling T; AstraZeneca, Wilmington, Delaware, USA., Danese M; Outcomes Insights, Agoura Hills, California, USA., Ulloa J; Outcomes Insights, Agoura Hills, California, USA., Danese S; Outcomes Insights, Agoura Hills, California, USA., Coleman CI; University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.; Evidence-based Practice Center, Hartford Hospital, Hartford, Connecticut, USA.

Publikováno v: Research and practice in thrombosis and haemostasis [Res Pract Thromb Haemost] 2024 Apr 27; Vol. 8 (4), pp. 102429. Date of Electronic Publication: 2024 Apr 27 (Print Publication: 2024).

Definition of factor Xa inhibitor-related, life-threatening gastrointestinal bleeding and guidance on when to use reversal therapy: A Delphi panel.

Autor: Fermann GJ; Department of Emergency Medicine University of Cincinnati Cincinnati Ohio USA., Cash BD; Division of Gastroenterology, Hepatology, and Nutrition University of Texas Health Science Center at Houston-McGovern Medical School Houston Texas USA., Coelho-Prabhu N; Division of Gastroenterology and Hepatology Mayo Clinic Rochester Minnesota USA., Maegele M; Department of Trauma and Orthopedic Surgery Cologne-Merheim Medical Center Institute of Research in Operative Medicine University Witten-Herdecke Cologne Germany., Bingisser R; Department of Emergency Medicine Universitätsspital Basel Basel Switzerland., Sehgal V; Department of Gastroenterology University College Hospital London London UK., Cohen AT; Department of Haematological Medicine Guy's and St. Thomas' Hospital London UK., Golden AH; RTI Health Solutions Research Triangle Park North Carolina USA., Russo J; RTI Health Solutions Research Triangle Park North Carolina USA., Price M; RTI Health Solutions Research Triangle Park North Carolina USA., Mangel A; RTI Health Solutions Research Triangle Park North Carolina USA., Koch B; AstraZeneca Medical Affairs Wilmington Delaware USA., Christoph MJ; AstraZeneca Medical Affairs Wilmington Delaware USA., Milling TJ Jr; Departments of Neurology and of Surgery and Perioperative Care Dell Medical School Austin Texas USA.

Publikováno v: Journal of the American College of Emergency Physicians open [J Am Coll Emerg Physicians Open] 2023 Oct 02; Vol. 4 (5), pp. e13043. Date of Electronic Publication: 2023 Oct 02 (Print Publication: 2023).

Correction to: Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate.

Autor: Sutton SS; Dorn Research Institute, Columbia VA Healthcare System (151), 6439 Garners Ferry Road, Columbia, SC, 29209, USA. sutton@cop.sc.edu.; Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA. sutton@cop.sc.edu., Magagnoli J; Dorn Research Institute, Columbia VA Healthcare System (151), 6439 Garners Ferry Road, Columbia, SC, 29209, USA.; Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA., Cummings TH; Dorn Research Institute, Columbia VA Healthcare System (151), 6439 Garners Ferry Road, Columbia, SC, 29209, USA.; Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA., Dettling T; Global Health Economics and Outcomes Research, AstraZeneca Rare Disease, Alexion, USA., Lovelace B; Global Health Economics and Outcomes Research, AstraZeneca Rare Disease, Alexion, USA., Christoph MJ; Global Health Economics and Outcomes Research, AstraZeneca Rare Disease, Alexion, USA., Hardin JW; Dorn Research Institute, Columbia VA Healthcare System (151), 6439 Garners Ferry Road, Columbia, SC, 29209, USA.; Department of Epidemiology and Biostatistics, University of South Carolina, 6439 Garners Ferry Road, Columbia, SC, 29209, USA.

Publikováno v: Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2023 Aug; Vol. 56 (2), pp. 360. Date of Electronic Publication: 2023 Jun 12.